At some point in our lives, many of us will find ourselves in a health fight we didn’t expect. A diagnosis. A test result. A moment that changes everything.
The Biotechnology Innovation Organization (BIO)’s new “Fight of Our Lives” campaign brings this reality into focus through the real stories of the patients, families, caregivers, researchers, and entrepreneurs who fight every day to find answers.
Over the past 50 years, American biotechnology has delivered extraordinary breakthroughs – preventing illness, improving treatment, and advancing therapies once thought impossible. But that momentum cannot be taken for granted. Nearly 200 million people in the United States live with at least one chronic condition, more than 30 million are affected by rare conditions, and cancer prevalence is projected to exceed 22 million by 2035. Millions are counting on the next generation of American innovation – and on our ability to build on this foundation to deliver what comes next.
Through powerful, human-centered storytelling, Fight of Our Lives brings that urgency into focus – elevating the people behind the progress and reinforcing what it will take to sustain innovation, strengthen economic leadership, and deliver the next generation of breakthroughs.
Meet the incredible people behind the first featured Fight of Our Lives stories:
- Ben, whose parents’ relentless search for answers uncovered a rare genetic condition – transforming him from an inconsolable baby to an unstoppable kid through access to a targeted therapy – and the broader scientific effort that made that breakthrough possible
- Marci, diagnosed with multiple sclerosis who, in partnership with her physician, became the first patient to receive an investigational CAR-T therapy, an innovative approach that reprograms the immune system and has shown unprecedented results in a disease once defined by progression.
- Katy, whose life changed in an instant due to an antibiotic-resistant infection, and who now advocates for awareness and innovation, alongside scientists working to harness artificial intelligence to develop a new generation of more effective antibiotics.
Together, these individuals reflect what American biotechnology makes possible – and why its progress matters to the more than 100 million Americans living with conditions it can help address. But millions more are still waiting for answers.
At a time when policy challenges and global competition are rapidly evolving, sustaining an environment that enables scientific progress is essential. American biotechnology is rewriting what comes next – bringing forward new options, new treatments, and new answers for the fight ahead.
This is the Fight of Our Lives.
